CG Invites Co., Ltd. Logo

CG Invites Co., Ltd.

Biopharma advancing precision medicine with drugs, mRNA vaccines, and digital therapeutics.

083790 | KO

Overview

Corporate Details

ISIN(s):
KR7083790006
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙8로 38 마곡동, 강서구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CG Invites Co., Ltd. is a biopharmaceutical company specializing in digital genomics and personalized precision medicine. Leveraging its core competency in developing novel chemical and biological drugs—such as Acelex (osteoarthritis), Ivaltinostat (pancreatic cancer), and Camrelizumab (immuno-oncology)—the company has expanded its focus to several key areas. These include whole genome sequencing, contributing to large-scale bio-data projects; the development of personalized, mRNA-based cancer vaccines targeting tumor-specific neoantigens; and digital therapeutics (DTx), exemplified by its HealthOnG platform for diabetes management. The company's strategy is to innovate within the digital genome market by integrating its drug development expertise with cutting-edge genomic and digital health technologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB
2025-08-14 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 34.7 KB
2025-08-08 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 2.7 MB
2025-07-25 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 16.5 KB
2025-07-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-07-10 00:00
Legal Proceedings Report
소송등의판결ㆍ결정 (신주발행 무효-취하)
Korean 5.3 KB
2025-07-10 00:00
Regulatory News Service
소속부변경
Korean 3.6 KB
2025-07-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 38.0 KB
2025-07-01 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 14.1 KB
2025-07-01 00:00
Regulatory News Service
소속부변경
Korean 3.6 KB
2025-06-05 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 134.5 KB
2025-06-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 28.6 KB
2025-06-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 29.4 KB
2025-06-05 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.8 MB

Automate Your Workflow. Get a real-time feed of all CG Invites Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CG Invites Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CG Invites Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.